Akari Therapeutics shareholders approve all proposals at adjourned 2024 AGM

Akari Therapeutics Plc

Initial June 27 meeting lacked quorum; adjourned to June 28.
All nine ordinary resolutions passed, including re-election of five directors.
Ratified BDO USA as independent auditor and Haysmacintyre as statutory auditor.
Non-binding advisory vote favored annual frequency for say-on-pay.
Votes in favor ranged from 5.7B to 6.5B of ~15.8B outstanding shares.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.